Published Date: 26 Apr 2023
Psilocybin, LSD, and MDMA are psychedelic drugs that may significantly lessen the severity of depression and anxiety symptoms in people with advanced cancer.
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
Smarter targeted radiotherapy just as effective for low-risk breast cancer and reduces risk of side effects
2.
Alcohol Causes Cancer. We Should Be Drinking Less.
3.
Additional Proof of the Different Cognitive Effects of ARSIs for Prostate Cancer.
4.
Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer
5.
Integrative palliative care is critical to improving mental health among pancreatic cancer patients
1.
From Muscle Soreness to Improved Endurance: The Benefits of Monitoring Lactic Acid Levels
2.
Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing
3.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
4.
What You Need to Know About the Early Warning Signs of Colon Cancer
5.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
4.
Navigating the Complexities of Ph Negative ALL - Part XIII
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation